As mentioned before, METTL3/14 knockout in CRC enhanced the response to anti–PD-1 therapy in constructed Patient-Derived Xenograft (PDX) mice by increasing the infiltration of cytotoxic CD8+ T cells into the tumor cell and a marked increase in the concentration of IFN-c, Cxcl9, and Cxcl10 in the tumor microenvironment (128). The gene discussed is CXCL9; the disease is neoplasm.